OncoMatch/Clinical Trials/NCT06782932
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Is NCT06782932 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for pancreatic cancer.
Treatment: AGEN2373 · Balstilimab · Cyclophosphamide · GVAX · AGEN2373 (RP2D) · Balstilimab · mKRASvax — The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-pancreatic cancer therapy
Exception: symptomatic therapies are allowed
Cannot have received: anti-cancer immunotherapy
Lab requirements
Blood counts
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Kidney function
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Liver function
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify